Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 2/20 | 0.50 |
| ▸ | MDM4 | O15151 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5887543 | 1.00 | MDM2 (0.50) | MDM2MDM4TP53CASP3KMT2A | |
| SCHEMBL5887246 | 0.91 | MDM2 (0.49) | MDM2MDM4TP53CASP3KMT2A | |
| SCHEMBL5887250 | 0.91 | MDM2 (0.49) | MDM2MDM4TP53CASP3KMT2A | |
| SCHEMBL13743302 | 0.91 | ATM (0.53) | MDM4TP53CASP3ATM | |
| SCHEMBL12531899 | 0.91 | ATM (0.53) | MDM4TP53CASP3ATM | |
| SCHEMBL2977877 | 0.91 | ATM (0.53) | MDM4TP53CASP3ATM | |
| SCHEMBL29401932 | 0.91 | ATM (0.53) | MDM4TP53CASP3ATM | |
| SCHEMBL5887683 | 0.90 | MDM2 (0.48) | MDM2MDM4TP53CASP3KMT2A | |
| SCHEMBL5887688 | 0.90 | MDM2 (0.48) | MDM2MDM4TP53CASP3KMT2A | |
| SCHEMBL21838224 | 0.90 | MDM4 (0.52) | MDM2MDM4TP53CASP3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7091373-B2 | Production method for biarylalanine | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-08-15 | — | — | US | disclosed |
| WO-2006037090-A2 | DRUG-PHOSPHATE CONJUGATES AS PRODRUGS | PURDUE RESEARCH FOUNDATION (US) | 2006-04-06 | — | — | WO | disclosed |
| US-20040024229-A1 | Production method for biarylalanine | SUMITOMO CHEMICAL COMPANY, LIMITED | 2004-02-05 | — | — | US | disclosed |
| EP-1346971-A1 | Production method for biarylalanine | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024229-A1 | Production method for biarylalanine | BCAT2, BCAT1, PAH | MDM2 605/4885MDM4 1405/4885TP53 4249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.